If Approved, Vaccine Can Be Ready For Mass Production<\/em><\/strong> by Year\u2019s End<\/em><\/strong> <\/p>\n\n\n\n By Local Talk Staff<\/em><\/p>\n\n\n\n As the race for a vaccine against COVID-19 continues, two companies have gotten much closer in achieving that goal.<\/p>\n\n\n\n On July 13, the U.S. Food and Drug Administration (FDA) designated two experimental vaccines as \u201cfast-tracked\u201d from pharmaceutical companies German based BioNTech and American-based Pfizer. Both companies join Moderna on the fast track list, as that company was approved back in May to find a vaccine for COVID-19, which is medically known as Novel Coronavirus SARS-CoV-2.<\/p>\n\n\n\n \u201cFast Track\u201d is a process designed to facilitate the development, and expedite the review, of new drugs and vaccines that are intended to treat or prevent serious conditions that have the potential to address an unmet medical need. This designation was granted based on preliminary data from Phase 1\/2 studies that are currently ongoing in the United States and Germany as well as animal immunogenicity studies.<\/p>\n\n\n\n The companies released early data from the ongoing U.S. Phase 1\/2 study for the product candidate BNT162b1 on July 1, 2020. The manuscript is available on the online preprint server medRxiv and is concurrently undergoing scientific peer-review for potential publication. Early data from the German trial of BNT162b1 are expected to be released in July.<\/p>\n\n\n\n The BNT162 program is evaluating at least four experimental vaccines, each of which represent a unique combination of messenger RNA (mRNA) format and target antigen. BNT162b1 and BNT162b2 are both nucleoside-modified RNAs, formulated in lipid nanoparticles. BNT162b1 encodes an optimized SARS-CoV-2 receptor-binding domain (RBD) antigen, while BNT162b2 encodes an optimized SARS-CoV-2 full-length spike protein antigen.<\/p>\n\n\n\n \u201cThe FDA\u2019s decision to grant these two COVID-19 vaccine candidates Fast Track designation signifies an important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2,\u201d said Peter Honig, Senior Vice President, Global Regulatory Affairs, Pfizer. \u201cWe look forward to continue working closely with the FDA throughout the clinical development of this program, Project Lightspeed, to evaluate the safety and efficacy of these vaccine candidates.\u201d<\/p>\n\n\n\n \u201cWe are pleased to have received Fast Track designation from the FDA for two of our vaccine candidates and look forward to working closely with the FDA, along with our partner Pfizer, to expedite the clinical development path forward,\u201d said \u00d6zlem T\u00fcreci, Chief Medical Officer at BioNTech.<\/p>\n\n\n\n The Project Lightspeed vaccine development program is based on BioNTech\u2019s proprietary mRNA-based technology platforms and supported by Pfizer\u2019s global vaccine development capabilities. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world. Pfizer and BioNTech are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront of all decision-making of both companies.<\/p>\n\n\n\n Subject to regulatory approval, the companies are expecting to start a Phase 2b\/3 trial as soon as later this month and are anticipating enrolling up to 30,000 subjects. If the ongoing studies are successful, and the vaccine candidate receives regulatory approval, the companies currently expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.<\/p>\n","protected":false},"excerpt":{"rendered":" If Approved, Vaccine Can Be Ready For Mass Production by Year\u2019s End By Local Talk Staff As the race for a vaccine against COVID-19 continues, two companies have gotten much closer in achieving that goal. On July 13, the U.S. Food and Drug Administration (FDA) designated two experimental vaccines as \u201cfast-tracked\u201d from pharmaceutical companies German […]<\/p>\n","protected":false},"author":2,"featured_media":406,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[47],"tags":[],"class_list":["post-504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"yoast_head":"\n